A clinical study to assess the safety of Imeglimin Tablets 500 mg in patients with diabetes.

Phase 4

Completed

• Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complications

• Registration Number: CTRI/2023/06/053621
• Lead Sponsor: Exemed Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2024-01-12
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 210

Inclusion Criteria

1. Male or Female Patients aged between 18 to 65 years (both inclusive) with diagnosis of Type 2 diabetes mellitus.

2. Treatment naïve patients with inadequately controlled with diet and exercise therapy alone for at least 3 months prior to screening and having inadequate glycemic control at screening defined as HbA1c levels of > 7.0% to = 8.5%.

3. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening / baseline visit.

4. Patients with no abnormality on 12-lead ECG at screening / baseline visit.

5. Patient with ability to understand and provide written informed consent form, which must have been obtained prior to screening.

6. Patients willing to comply with the protocol requirements.

Exclusion Criteria

1. Patients with a history of Type 1 diabetes mellitus or secondary diabetes mellitus or diabetes insipidus.

2. Patients with a history of metabolic acidosis or diabetic ketoacidosis.

3. Patients with fasting plasma glucose (FPG) > 200 mg/dL at screening.

4. Patients with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 [using the Modification of Diet in Renal Disease (MDRD) equation] at screening.

5. Patients with clinically significant impaired hepatic function (SGOT & SGPT more than 3X the UNL and/or Total bilirubin more than 2X the UNL) at screening.

6. Patients with a history of congestive heart failure defined as New York Heart Association (NYHA) class III/IV, unstable or acute congestive heart failure.

7. Patients with significant cardiovascular history defined as: myocardial infarction, unstable angina pectoris, transient ischemic attack, unstable or previously undiagnosed arrhythmia, cardiac surgery or revascularization (coronary angioplasty or bypass grafts), or cerebrovascular accident.

8. Patients with uncontrolled hypertension with sitting systolic BP = 160 mmHg and/or diastolic BP = 100 mmHg at screening.

9. Patients with a history of anaemia or haemoglobinopathy and/or haemoglobin < 10 g/dL for men; haemoglobin < 9 g/dL for women at screening.

10. Patients with known hypersensitivity to any of the ingredients of study medication.

11. Patients receiving treatment with systemic corticosteroids.

12. Pregnant or breast-feeding or expecting to conceive within the projected duration of the study.

13. Female patients who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods (like hormonal, barrier methods or intrauterine device).

14. Patients with history of any malignancy.

15. Patients with known case of infection with hepatitis B, hepatitis C or HIV.

16. Patients with donation or transfusion of blood, plasma, or platelets within the past 3 months prior to screening.

17. Patients with a history of substance abuse or dependence that in the opinion of the Investigator is considered to interfere with the patient’s participation in the study.

18. Patients with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.

19. Patients currently taking any of the prohibited medications(s) and inability/unwillingness to discontinue them for the entire study period.

20. Suspected inability or unwillingness to comply with the study procedures.

21. Patient with any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient.

Study & Design

• Study Type: PMS
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean change in glycosylated haemoglobin (HbA1c) from baseline to end of the study visit (week 16).Timepoint: At Screening/baseline visit, <br/ ><br>Visit 4 [Week 12/Day 84(±4)] and <br/ ><br>Visit 5 [Week 16/Day 112(±4)].